• Presented at 16th European Crohn´s and Colitis Organisation (ECCO) Virtual Meeting (2021)

  • Collaborators: Takeda Pharmaceuticals International, Humanitas University, Imelda Hospital

  • Authors: Fiorino G, Bent-Ennakhil N, Varriale P, Braegger F, Hoefkens E

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract, with no cure currently available. The increasingly complex and diverse treatment paradigm for IBD suggests that along with clinical guidelines, patient engagement through shared decision-making engages patients in treatment decisions and optimizes the chance of a chosen therapy matching their personal preferences. Adequate information and fair presentation of the trade-off between the risks and benefits of treatment are critical for patients’ participation in medical decisions.

Objective:  This patient survey aimed to describe the demographics and clinical characteristics of respondents and patient-rated preferences towards existing treatment options and impact on quality of life (QoL); here, we present patient demographics, clinical characteristics, and impact of IBD on QoL.